Program Description

For the first time in the history of AD management, a class of therapy designed to alter the disease course for patients is finally a reality in the form of anti-amyloid beta monoclonal antibodies (anti-Aβ mAbs). And while this development represents a monumental shift in the treatment of this progressive disease, it unlocks a whole host of new challenges for clinicians in the form of significant adjustment of practice norms. On top of requiring a baseline understanding of a new class of medication, this advance also requires a variety of logistical changes that institutions must learn to navigate. Accordingly, this program explores general principles of anti-Aβ mAb implementation alongside practical questions provided directly by an institution in the early phases of setting up their own processes for initiation and use of these agents.